Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evan Goldfischer

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Current Medical Research and Opinion|December 3, 2014
Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafilEdward Kim, Allen Seftel, Evan Goldfischer, et al.
Urology Practice|May 8, 2023
Reply by AuthorsRobert A Dowling, Qingxia Chen, Evan Goldfischer, et al.
Urology Practice|April 27, 2023
Surgical Stone Treatment: Patterns May Predict Performance on Episode-based Cost Measure in the Quality Payment ProgramRobert A Dowling, Qingxia Chen, Evan Goldfischer, et al.
Urology Practice|February 7, 2024
Telemedicine Utilization in the COVID-19 Era: Patterns of Care in Community Urology PracticeRobert A Dowling, Song Zhang, Evan Goldfischer, et al.
The Journal of Urology|November 16, 2010
Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trialAllen Seftel, Evan Goldfischer, Edward D Kim, et al.
The Journal of Sexual Medicine|February 29, 2008
Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in men over 65 years of age: results from Multiple Observations in Men with ED in National Tadalafil Study in the United StatesIra D Sharlip, Bryan P Shumaker, Lawrence S Hakim, et al.
Urology|February 21, 2012
Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trialEvan Goldfischer, John J Kowalczyk, William R Clark, et al.
Journal of Sex & Marital Therapy|December 21, 2012
Validity of the decreased sexual desire screener for diagnosing hypoactive sexual desire disorderAnita H Clayton, Evan Goldfischer, Irwin Goldstein, et al.
Urology|January 7, 2019
A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and UtilityScott Eggener, Lawrence I Karsh, Tim Richardson, et al.
Urology|April 30, 2017
Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational CohortGregg Eure, Raymond Germany, Robert Given, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Current Medical Research and Opinion|December 3, 2014
Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafilEdward Kim, Allen Seftel, Evan Goldfischer, et al.
Urology Practice|May 8, 2023
Reply by AuthorsRobert A Dowling, Qingxia Chen, Evan Goldfischer, et al.
Urology Practice|April 27, 2023
Surgical Stone Treatment: Patterns May Predict Performance on Episode-based Cost Measure in the Quality Payment ProgramRobert A Dowling, Qingxia Chen, Evan Goldfischer, et al.
Urology Practice|February 7, 2024
Telemedicine Utilization in the COVID-19 Era: Patterns of Care in Community Urology PracticeRobert A Dowling, Song Zhang, Evan Goldfischer, et al.
The Journal of Urology|November 16, 2010
Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trialAllen Seftel, Evan Goldfischer, Edward D Kim, et al.
The Journal of Sexual Medicine|February 29, 2008
Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in men over 65 years of age: results from Multiple Observations in Men with ED in National Tadalafil Study in the United StatesIra D Sharlip, Bryan P Shumaker, Lawrence S Hakim, et al.
Urology|February 21, 2012
Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trialEvan Goldfischer, John J Kowalczyk, William R Clark, et al.
Journal of Sex & Marital Therapy|December 21, 2012
Validity of the decreased sexual desire screener for diagnosing hypoactive sexual desire disorderAnita H Clayton, Evan Goldfischer, Irwin Goldstein, et al.
Urology|January 7, 2019
A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and UtilityScott Eggener, Lawrence I Karsh, Tim Richardson, et al.
Urology|April 30, 2017
Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational CohortGregg Eure, Raymond Germany, Robert Given, et al.
Pageof 2